PortalPublikationenA roadmap for serum biomarkers for hepatitis B virus: curren...

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Standard

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. / Kramvis, Anna; Chang, Kyong-Mi; Dandri, Maura; Farci, Patrizia; Glebe, Dieter; Hu, Jianming; Janssen, Harry L A; Lau, Daryl T Y; Penicaud, Capucine; Pollicino, Teresa; Testoni, Barbara; Van Bömmel, Florian; Andrisani, Ourania; Beumont-Mauviel, Maria; Block, Timothy M; Chan, Henry L Y; Cloherty, Gavin A; Delaney, William E; Geretti, Anna Maria; Gehring, Adam; Jackson, Kathy; Lenz, Oliver; Maini, Mala K; Miller, Veronica; Protzer, Ulrike; Yang, Jenny C; Yuen, Man-Fung; Zoulim, Fabien; Revill, Peter A.

in: NAT REV GASTRO HEPAT, Jahrgang 19, Nr. 11, 11.2022, S. 727-745.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Kramvis, A, Chang, K-M, Dandri, M, Farci, P, Glebe, D, Hu, J, Janssen, HLA, Lau, DTY, Penicaud, C, Pollicino, T, Testoni, B, Van Bömmel, F, Andrisani, O, Beumont-Mauviel, M, Block, TM, Chan, HLY, Cloherty, GA, Delaney, WE, Geretti, AM, Gehring, A, Jackson, K, Lenz, O, Maini, MK, Miller, V, Protzer, U, Yang, JC, Yuen, M-F, Zoulim, F & Revill, PA 2022, 'A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook', NAT REV GASTRO HEPAT, Jg. 19, Nr. 11, S. 727-745. https://doi.org/10.1038/s41575-022-00649-z

APA

Kramvis, A., Chang, K-M., Dandri, M., Farci, P., Glebe, D., Hu, J., Janssen, H. L. A., Lau, D. T. Y., Penicaud, C., Pollicino, T., Testoni, B., Van Bömmel, F., Andrisani, O., Beumont-Mauviel, M., Block, T. M., Chan, H. L. Y., Cloherty, G. A., Delaney, W. E., Geretti, A. M., ... Revill, P. A. (2022). A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. NAT REV GASTRO HEPAT, 19(11), 727-745. https://doi.org/10.1038/s41575-022-00649-z

Vancouver

Kramvis A, Chang K-M, Dandri M, Farci P, Glebe D, Hu J et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. NAT REV GASTRO HEPAT. 2022 Nov;19(11):727-745. https://doi.org/10.1038/s41575-022-00649-z

Bibtex

@article{3703ce60070843109f969cfc3cce1c3d,
title = "A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook",
abstract = "Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.",
keywords = "Humans, Hepatitis B virus, Hepatitis B, Chronic/diagnosis, Antiviral Agents/therapeutic use, Virus Replication, Biomarkers, Disease Progression, Hepatitis B/diagnosis",
author = "Anna Kramvis and Kyong-Mi Chang and Maura Dandri and Patrizia Farci and Dieter Glebe and Jianming Hu and Janssen, {Harry L A} and Lau, {Daryl T Y} and Capucine Penicaud and Teresa Pollicino and Barbara Testoni and {Van B{\"o}mmel}, Florian and Ourania Andrisani and Maria Beumont-Mauviel and Block, {Timothy M} and Chan, {Henry L Y} and Cloherty, {Gavin A} and Delaney, {William E} and Geretti, {Anna Maria} and Adam Gehring and Kathy Jackson and Oliver Lenz and Maini, {Mala K} and Veronica Miller and Ulrike Protzer and Yang, {Jenny C} and Man-Fung Yuen and Fabien Zoulim and Revill, {Peter A}",
note = "{\textcopyright} 2022. Springer Nature Limited.",
year = "2022",
month = nov,
doi = "10.1038/s41575-022-00649-z",
language = "English",
volume = "19",
pages = "727--745",
journal = "NAT REV GASTRO HEPAT",
issn = "1759-5045",
publisher = "NATURE PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

AU - Kramvis, Anna

AU - Chang, Kyong-Mi

AU - Dandri, Maura

AU - Farci, Patrizia

AU - Glebe, Dieter

AU - Hu, Jianming

AU - Janssen, Harry L A

AU - Lau, Daryl T Y

AU - Penicaud, Capucine

AU - Pollicino, Teresa

AU - Testoni, Barbara

AU - Van Bömmel, Florian

AU - Andrisani, Ourania

AU - Beumont-Mauviel, Maria

AU - Block, Timothy M

AU - Chan, Henry L Y

AU - Cloherty, Gavin A

AU - Delaney, William E

AU - Geretti, Anna Maria

AU - Gehring, Adam

AU - Jackson, Kathy

AU - Lenz, Oliver

AU - Maini, Mala K

AU - Miller, Veronica

AU - Protzer, Ulrike

AU - Yang, Jenny C

AU - Yuen, Man-Fung

AU - Zoulim, Fabien

AU - Revill, Peter A

N1 - © 2022. Springer Nature Limited.

PY - 2022/11

Y1 - 2022/11

N2 - Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.

AB - Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.

KW - Humans

KW - Hepatitis B virus

KW - Hepatitis B, Chronic/diagnosis

KW - Antiviral Agents/therapeutic use

KW - Virus Replication

KW - Biomarkers

KW - Disease Progression

KW - Hepatitis B/diagnosis

U2 - 10.1038/s41575-022-00649-z

DO - 10.1038/s41575-022-00649-z

M3 - SCORING: Review article

C2 - 35859026

VL - 19

SP - 727

EP - 745

JO - NAT REV GASTRO HEPAT

JF - NAT REV GASTRO HEPAT

SN - 1759-5045

IS - 11

ER -